Found 6 matching trials
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease PHASE2 STA-5326 is an oral experimental drug that has been shown to block the rele...
Show More Learn More & Join Trial
STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency PHASE1 This study will determine whether an experimental medicine, STA-5326 mesyla...
Show More Location
National Institutes of Health Clinical Center, 9000 Rockville Pike
Learn More & Join Trial
Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease PHASE2 STA-5326 is an experimental drug that has been shown to block the release o...
Show More Location
Gastroenterology Associates
Learn More & Join Trial
A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes PHASE2 It is not fully clear how rheumatoid arthritis originates and develops, but...
Show More Location
Academic Medical Center
Learn More & Join Trial
The Immunological and Blood Effects of STA-5326 Mesylate on Patients With Crohn's Disease PHASE2 This study will test whether a new experimental drug called STA-5326 mesyla...
Show More Location
National Institute of Allergy and Infectious Diseases (NIAID)
Learn More & Join Trial
STA-5326 in Crohn's Disease Patients PHASE1 The purpose of this study is to determine the safety and tolerability of ST...
Show More Location
Advanced Clinical Therapeutics
Learn More & Join Trial